X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1756) 1756
Book Review (244) 244
Publication (134) 134
Newsletter (13) 13
Conference Proceeding (7) 7
Book Chapter (5) 5
Dissertation (3) 3
Magazine Article (2) 2
Newspaper Article (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1461) 1461
clarithromycin (1277) 1277
humans (1148) 1148
pharmacology & pharmacy (802) 802
male (709) 709
female (589) 589
pharmacokinetics (453) 453
adult (445) 445
azithromycin (402) 402
microbiology (364) 364
erythromycin (344) 344
anti-bacterial agents - therapeutic use (339) 339
animals (337) 337
anti-bacterial agents - pharmacology (336) 336
middle aged (331) 331
clarithromycin - pharmacology (309) 309
anti-bacterial agents - pharmacokinetics (299) 299
clarithromycin - pharmacokinetics (285) 285
drug interactions (283) 283
anti-bacterial agents - administration & dosage (282) 282
clarithromycin - administration & dosage (280) 280
clarithromycin - therapeutic use (267) 267
infectious diseases (262) 262
antibiotics (255) 255
aged (253) 253
macrolides (236) 236
microbial sensitivity tests (227) 227
infection (212) 212
drug therapy, combination (201) 201
treatment outcome (198) 198
helicobacter pylori (191) 191
helicobacter infections - drug therapy (182) 182
anti-bacterial agents - adverse effects (167) 167
administration, oral (159) 159
area under curve (153) 153
clarithromycin - adverse effects (151) 151
adolescent (149) 149
in-vitro (145) 145
therapy (143) 143
amoxicillin (142) 142
efficacy (135) 135
abridged index medicus (133) 133
macrolide antibiotics (132) 132
analysis (117) 117
gastroenterology & hepatology (115) 115
mice (115) 115
drug administration schedule (114) 114
pharmacology (114) 114
drug therapy (112) 112
infections (112) 112
antimicrobial agents (106) 106
azithromycin - pharmacology (105) 105
resistance (105) 105
helicobacter pylori - drug effects (104) 104
azithromycin - pharmacokinetics (103) 103
omeprazole (103) 103
health aspects (99) 99
community-acquired pneumonia (97) 97
aged, 80 and over (96) 96
child (96) 96
dose-response relationship, drug (95) 95
cross-over studies (94) 94
medicine & public health (94) 94
macrolide (91) 91
roxithromycin (91) 91
eradication (89) 89
clarithromycin - blood (88) 88
erythromycin - pharmacology (88) 88
pneumonia (88) 88
rats (88) 88
azithromycin - therapeutic use (86) 86
pharmacology/toxicology (86) 86
research (86) 86
anti-bacterial agents - blood (84) 84
metronidazole (83) 83
dosage and administration (82) 82
time factors (82) 82
double-blind method (81) 81
drug resistance, bacterial (81) 81
triple therapy (81) 81
immunology (80) 80
internal medicine (80) 80
medicine, general & internal (80) 80
half-life (79) 79
proton pump inhibitors (79) 79
azithromycin - administration & dosage (78) 78
drugs (78) 78
metabolism (78) 78
lansoprazole (76) 76
prospective studies (76) 76
respiratory system (76) 76
care and treatment (75) 75
erythromycin - analogs & derivatives (75) 75
erythromycin - pharmacokinetics (75) 75
management (75) 75
levofloxacin (72) 72
drug-interactions (70) 70
rifampin (70) 70
tuberculosis (70) 70
amoxicillin - therapeutic use (69) 69
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1713) 1713
Japanese (28) 28
French (10) 10
Spanish (8) 8
German (6) 6
Chinese (4) 4
Portuguese (4) 4
Russian (3) 3
Hungarian (1) 1
Italian (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Biopharmaceutics & Drug Disposition, ISSN 0142-2782, 01/2018, Volume 39, Issue 1, pp. 3 - 17
In recent years, physiologically based PharmacoKinetic (PBPK) modeling has received growing interest as a useful tool for the assessment of drug... 
PBPK | drug‐drug interactions | physiologically‐based pharmacokinetic modeling | cytochrome P450 | Simcyp | drug-drug interactions | physiologically-based pharmacokinetic modeling | SYSTEMIC ANTIMYCOTICS KETOCONAZOLE | THEOPHYLLINE PHARMACOKINETICS | INCREASES PLASMA-CONCENTRATIONS | ITRACONAZOLE | HEPATIC CYP3A | DOSE PHARMACOKINETICS | ORAL MIDAZOLAM | CYTOCHROME-P450 3A ACTIVITY | PHARMACOLOGY & PHARMACY | IN-VIVO PROBE | HUMAN-POPULATIONS | Paroxetine - pharmacokinetics | Rifampin - pharmacokinetics | Cytochrome P-450 CYP2D6 Inhibitors - pharmacokinetics | Humans | Ketoconazole - pharmacokinetics | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Ciprofloxacin - pharmacokinetics | Fluconazole - pharmacokinetics | Drug Interactions | Cytochrome P-450 Enzyme Inducers - pharmacokinetics | Itraconazole - pharmacokinetics | Models, Biological | Computer Simulation | Quinidine - pharmacokinetics | Clarithromycin - pharmacokinetics | Software | Paroxetine | Usage | Drug interactions | Antifungal agents | Cytochrome P-450 | Ciprofloxacin | Rifampin | Genetic polymorphisms | Cytochrome | Competition | Clarithromycin | Fluconazole | Ketoconazole | Cytochrome P450 | Pharmacology | CYP1A2 protein | Minority & ethnic groups | Modulators | Computer programs | Inhibitors | Quinidine | Mathematical models | Pharmacokinetics | CYP2D6 protein | Itraconazole | Index Medicus
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 02/2018, Volume 58, Issue 2, pp. 180 - 192
Journal Article
The American Journal of Cardiology, ISSN 0002-9149, 2004, Volume 94, Issue 9, pp. 1140 - 1146
Three-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors (statins) are first-line treatments for hypercholesterolemia. Although exceedingly well... 
CLARITHROMYCIN | INDUCED RHABDOMYOLYSIS | LOVASTATIN | CARDIAC & CARDIOVASCULAR SYSTEMS | CONCOMITANT USE | ERYTHROMYCIN | FATAL RHABDOMYOLYSIS | ITRACONAZOLE | ROSUVASTATIN | DRUG-INTERACTION | CYCLOSPORINE | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Pyrroles - pharmacokinetics | Cytochrome P-450 Enzyme Inhibitors | Cytochrome P-450 Enzyme System - administration & dosage | Area Under Curve | Heptanoic Acids - pharmacokinetics | Humans | Middle Aged | Mibefradil - pharmacokinetics | Male | Protein Synthesis Inhibitors - administration & dosage | Verapamil - administration & dosage | Dose-Response Relationship, Drug | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Antiprotozoal Agents - pharmacokinetics | Drug Interactions | Itraconazole - pharmacokinetics | Pyrroles - administration & dosage | Clarithromycin - pharmacokinetics | Mibefradil - administration & dosage | Clarithromycin - administration & dosage | Heptanoic Acids - administration & dosage | Adult | Female | Itraconazole - administration & dosage | Drug Therapy, Combination | Double-Blind Method | Simvastatin - administration & dosage | Verapamil - pharmacokinetics | Biomarkers - blood | Simvastatin - pharmacokinetics | Protein Synthesis Inhibitors - pharmacokinetics | Atorvastatin Calcium | Anticholesteremic Agents - pharmacokinetics | Pravastatin - administration & dosage | Anticholesteremic Agents - administration & dosage | Adolescent | Antiprotozoal Agents - administration & dosage | Calcium Channel Blockers - administration & dosage | Creatine Kinase - drug effects | Calcium Channel Blockers - pharmacokinetics | Pravastatin - pharmacokinetics | Index Medicus | Abridged Index Medicus
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 09/2013, Volume 76, Issue 3, pp. 455 - 466
AimsThe anticoagulant rivaroxaban is an oral, direct Factor Xa inhibitor for the management of thromboembolic disorders. Metabolism and excretion involve... 
cytochrome | glycoprotein | rivaroxaban | drug interactions | healthy subjects | 450 | P-glycoprotein | Rivaroxaban | Healthy subjects | Cytochrome P450 | Drug interactions | BAY-59-7939 | SAFETY | PREVENTION | PHARMACODYNAMICS | cytochrome P450 | PROTEASE INHIBITORS | IN-VITRO | FACTOR-XA INHIBITOR | ERYTHROMYCIN | PHARMACOLOGY & PHARMACY | LIVER-MICROSOMES | Anticoagulants - administration & dosage | Cytochrome P-450 Enzyme Inhibitors | Erythromycin - pharmacology | Ketoconazole - administration & dosage | Humans | Middle Aged | Cytochrome P-450 Enzyme System - metabolism | Midazolam - administration & dosage | Substrate Specificity | Metabolic Clearance Rate | Thiophenes - administration & dosage | Ketoconazole - pharmacology | Enzyme Inhibitors - administration & dosage | Young Adult | Drug Interactions | Enzyme Inhibitors - pharmacokinetics | Clarithromycin - pharmacokinetics | Clarithromycin - administration & dosage | Adult | Morpholines - administration & dosage | Enzyme Inhibitors - pharmacology | Ketoconazole - pharmacokinetics | Midazolam - pharmacokinetics | Cytochrome P-450 CYP3A - administration & dosage | Erythromycin - administration & dosage | ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors | ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism | Thiophenes - pharmacokinetics | Erythromycin - pharmacokinetics | Cytochrome P-450 CYP3A - metabolism | Adolescent | Anticoagulants - pharmacokinetics | Morpholines - pharmacokinetics | Clarithromycin - pharmacology | Midazolam - pharmacology | Ketoconazole | Protease inhibitors | Fluconazole | Proteases | Cytochrome P-450 | Dosage and administration | Anticoagulants (Medicine) | Erythromycin | Thromboembolism | Index Medicus
Journal Article
Journal Article
Journal Article
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 2012, Volume 186, Issue 6, pp. 559 - 565
Journal Article
Advances in Therapy, ISSN 0741-238X, 09/2016, Volume 33, Issue 9, pp. 1519 - 1535
Journal Article